News
VALN
7.26
+1.21%
0.09
What Analysts Are Saying About Valneva Stock
Valneva SE is a vaccine company focused on developing life-saving vaccines. The average price target for Valneva is $26.0. 8 analysts have provided ratings for the company in the past three months. The company has a 12-month price target of $25.00.
Benzinga · 4d ago
Valneva Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $26 Price Target
Benzinga · 4d ago
Strong Buy Rating for Valneva as Ixchiq Vaccine Shows Significant Market Potential
TipRanks · 4d ago
Valneva Secures Multi-Million Grant for Vaccine Access
TipRanks · 4d ago
Weekly Report: what happened at VALN last week (0715-0719)?
Weekly Report · 4d ago
CEPI And EU Grant Valneva $41.3M To Enhance Global Reach Of Chikungunya Vaccine IXCHIQ
Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine. Funding will support clinical trials in vulnerable groups, such as children and pregnant women. IXCHIQ® is already approved for use in adults 18 years of age and older.
Benzinga · 4d ago
CEPI EXPANDS PARTNERSHIP WITH VALNEVA WITH A $41.3 MILLION GRANT TO SUPPORT BROADER ACCESS TO THE WORLD’S FIRST CHIKUNGUNYA VACCINE
Reuters · 4d ago
Kepler Capital Keeps Their Buy Rating on Valneva (0OB3)
TipRanks · 6d ago
Valneava and Pfizer Nearing Lyme Vaccine Milestone
TipRanks · 07/18 19:17
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Pfizer and Valneva have completed the primary vaccination series of Lyme disease vaccine candidate VLA15. Lyme disease is a bacterial infection that can be spread to humans by infected ticks. The vaccine candidate has shown a favorable safety profile in all clinical trials. Pfizer plans to submit marketing applications with the FDA in 2026.
Benzinga · 07/18 18:05
BRIEF-Valneva Says Co And Pfizer Announce Primary Vaccination Series Completion
Valneva says Co And Pfizer Announce Primary Vaccination Series Completion. Company says primary vaccine series to be followed by a boost in production in 1 year. Valneva and Pfizer are working together to develop a new vaccine for lyme disease. The company says it is in phase 3 of a clinical trial.
Reuters · 07/17 20:03
PHASE 3 VALOR LYME DISEASE TRIAL: VALNEVA AND PFIZER ANNOUNCE PRIMARY VACCINATION SERIES COMPLETION
Reuters · 07/17 20:00
VALNEVA SE - VLA15 HAS SHOWN FAVORABLE SAFETY PROFILE TO DATE
Reuters · 07/17 20:00
VALNEVA SE: PFIZER PLANS TO SUBMIT A BIOLOGICS LICENSE APPLICATION (BLA) TO FDA & EMAI N 2026.
Reuters · 07/17 20:00
Weekly Report: what happened at VALN last week (0708-0712)?
Weekly Report · 07/15 09:16
Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine
NASDAQ · 07/08 16:45
Weekly Report: what happened at VALN last week (0701-0705)?
Weekly Report · 07/08 09:16
Valneva’s Chikungunya Vaccine Wins European Approval
TipRanks · 07/01 10:37
More
Webull provides a variety of real-time VALN stock news. You can receive the latest news about Valneva Se through multiple platforms. This information may help you make smarter investment decisions.
About VALN
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.